Aytu Biopharma, Inc.
AYTU
$1.27
$0.010.79%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 68.76M | 71.29M | 72.53M | 85.29M | 90.03M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 68.76M | 71.29M | 72.53M | 85.29M | 90.03M |
| Cost of Revenue | 21.66M | 20.37M | 20.56M | 27.39M | 31.08M |
| Gross Profit | 47.10M | 50.92M | 51.97M | 57.90M | 58.95M |
| SG&A Expenses | 43.58M | 43.88M | 45.48M | 48.49M | 56.48M |
| Depreciation & Amortization | 4.45M | 4.45M | 4.45M | 4.34M | 4.24M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 72.31M | 71.31M | 73.27M | 82.42M | 94.23M |
| Operating Income | -3.54M | -19.00K | -740.00K | 2.87M | -4.20M |
| Income Before Tax | -4.68M | -3.67M | -12.64M | -11.17M | -15.73M |
| Income Tax Expenses | 1.06M | 2.13M | 1.72M | 1.03M | 780.00K |
| Earnings from Continuing Operations | -5.75 | -5.79 | -14.36 | -12.20 | -16.51 |
| Earnings from Discontinued Operations | 504.00K | -458.00K | -1.49M | -1.49M | -1.49M |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -5.24M | -6.25M | -15.84M | -13.68M | -18.00M |
| EBIT | -3.54M | -19.00K | -740.00K | 2.87M | -4.20M |
| EBITDA | 3.09M | 7.06M | 6.76M | 10.54M | 3.74M |
| EPS Basic | -0.97 | -1.14 | -2.86 | -2.64 | -4.05 |
| Normalized Basic EPS | 0.14 | 0.13 | -0.96 | -0.94 | -2.00 |
| EPS Diluted | -1.76 | -1.54 | -2.87 | -2.64 | -4.05 |
| Normalized Diluted EPS | 0.01 | 0.05 | -0.96 | -0.94 | -2.00 |
| Average Basic Shares Outstanding | 23.35M | 22.74M | 22.15M | 20.68M | 18.87M |
| Average Diluted Shares Outstanding | 28.74M | 25.77M | 22.15M | 20.68M | 18.87M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
